Discontinued — last reported Q4 '25
Redeemable noncontrolling interests in subsidiaries
Quest Diagnostics Redeemable noncontrolling interests in subsidiaries decreased by 1.3% to $79.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.5%, from $81.00M to $79.00M. Over 5 years (FY 2020 to FY 2025), Redeemable noncontrolling interests in subsidiaries shows relatively stable performance with a -0.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase represents a potential future cash obligation that could impact liquidity or capital allocation.
Detailed definition
This represents the portion of equity in a subsidiary that is held by third parties but is subject to redemption feature...
Peer comparison
Specific to companies with complex joint venture or subsidiary structures; peers with similar structures will report this similarly.
other_redeemable_noncontrolling_interest_equity_carrying_amountHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $78.00M | $79.00M | $79.00M | $78.00M | $77.00M | $77.00M | $77.00M | $77.00M | $77.00M | $76.00M | $76.00M | $77.00M | $79.00M | $80.00M | $83.00M | $81.00M | $81.00M | $81.00M | $80.00M | $79.00M |
| QoQ Change | — | +1.3% | +0.0% | -1.3% | -1.3% | +0.0% | +0.0% | +0.0% | +0.0% | -1.3% | +0.0% | +1.3% | +2.6% | +1.3% | +3.8% | -2.4% | +0.0% | +0.0% | -1.2% | -1.3% |
| YoY Change | — | — | — | — | -1.3% | -2.5% | -2.5% | -1.3% | +0.0% | -1.3% | -1.3% | +0.0% | +2.6% | +5.3% | +9.2% | +5.2% | +2.5% | +1.3% | -3.6% | -2.5% |
Redeemable noncontrolling interests in subsidiaries at Other Companies
Frequently Asked Questions
- What is Quest Diagnostics's redeemable noncontrolling interests in subsidiaries?
- Quest Diagnostics (DGX) reported redeemable noncontrolling interests in subsidiaries of $79.00M in Q1 2026.
- How has Quest Diagnostics's redeemable noncontrolling interests in subsidiaries changed year-over-year?
- Quest Diagnostics's redeemable noncontrolling interests in subsidiaries decreased by 2.5% year-over-year, from $81.00M to $79.00M.
- What is the long-term trend for Quest Diagnostics's redeemable noncontrolling interests in subsidiaries?
- Over 5 years (2020 to 2025), Quest Diagnostics's redeemable noncontrolling interests in subsidiaries has grown at a -0.5% compound annual growth rate (CAGR), from $82.00M to $80.00M.
- What does redeemable noncontrolling interests in subsidiaries mean?
- Equity held by others in a subsidiary that the company may be required to buy back.